‘Challenging’ Times For Sandoz As COVID Bites
Sales And Core Operating Profit See Double-Digit Declines Despite Biopharma Growth
Executive Summary
Sandoz saw both its sales and core operating profit experience double-digit drops in what management described as a “challenging” first quarter of 2021. However, its performance is expected to stabilize in the back end of the year as pandemic-related pressures ease.
You may also be interested in...
Sandoz CEO Saynor Signals No Change To Focus Amid Strategic Review
Sandoz CEO Richard Saynor says the generics and biosimilars giant’s focus and strategy remain “unchanged” in the wake of a long-awaited announcement by parent company Novartis that it is exploring its options for the Sandoz business.
$10bn Sandoz Business May Be Sold Or Spun As Novartis Weighs Options
Novartis finally has confirmed plans to begin a strategic review for its Sandoz generics and biosimilars business, following years of conjecture and suggestions from the market. However, the originator stressed that it will take its time with a decision, while underlining that keeping Sandoz is among its choices.
Consolidation And COVID See Industry Top 10 Rankings Rewritten
After an extraordinary year that saw demand patterns and the supply chain upended by the COVID-19 pandemic, as well as a major merger that has transformed one of the global off-patent industry’s biggest players, the leaders of the pack in the Generics Bulletin Top 50 have once again seen significant changes in 2021.